Pharmaceutical Substances - Version 4.7
The version 4.7 of Pharmaceutical Substances was launched in October 2019.
Pharmaceutical Substances 4.7 contains 14 new APIs and a total of 42,811 structures, 12,434 reactions, and 2,735 active pharmaceutical ingredients.
"The new release comprises again innovative drugs with FDA priority review designation and accelerated approval.
Amongst them are the new anticancer drugs Alpelisib from Novartis against breast cancer, Darolutamide developed by Bayer for prostate cancer treatment, Erdafitinib from Janssen for urethial carcinoma and Selinexor/Karyopharm Therapeutics against multiple myeloma.
In addition, the update contains the two antiinfectives Relebactam from Merck and Pretomanid developed by TB Alliance/Mylan against tuberculosis.
This latest release also describes the peptide Bremelanotide as first drug against hypoactive sexual desire disorder, Revefenacin as new inhalative anticholinergic bronchodilator, Siponimod for multiple sclerosis treatment and Solriamfetol against excessive daytime sleepiness."
Authors Prof. Axel Kleemann, Prof. Bernhard Kutscher and Dr. Dietmar Reichert
Additionally, the following APIs have been updated: